Acute promyelocytic leukemia (APL) is a rapidly fatal disease without timely treatment.¹ A recent breakthrough from the University of Hong Kong’s LKS Faculty of Medicine (HKUMed) is changing the global treatment landscape of APL with the development of an oral formulation of arsenic trioxide (oral-ATO).^2-7 Backed by over 20 years of clinical data, oral-ATO has now received orphan drug designation (ODD) from both the United States (US) Food and Drug Administration (FDA) and European Medicines Agency (EMA).^1,8,9 Led by Dr. Singh, Gill Harinder Harry, Clinical Associate Professor at HKUMed, the team is pioneering a new era in APL treatment, bringing this life-saving innovation from Hong Kong to the global stage.^2,7

The United States (US) Food and Drug Administration (FDA) has approved marstacimab-hncq, an anti-tissue factor pathway inhibitor, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (HA) without factor VIII inhibitors or hemophilia B (HB) without factor IX inhibitors (neutralizing antibodies).¹ The approval was based on results from the phase 3 BASIS trial, which showed a reduction in the annualized bleeding rate (ABR) with marstacimab-hncq compared to on-demand treatment and routine prophylaxis in patients with HA or HB without inhibitors.^1,2

Patients with multiple myeloma (MM) are highly susceptible to developing relapsed and refractory (RR) disease towards lenalidomide and proteasome inhibitors (PIs) and require new active treatments at relapse. As such, novel treatment options like isatuximab, a monoclonal antibody (mAb) that targets